Cargando…
PRESTO 2: An International Survey to Evaluate Patients’ Injection Experiences with the Latest Devices/Formulations of Long-Acting Somatostatin Analog Therapies for Neuroendocrine Tumors or Acromegaly
INTRODUCTION: Real-world data evaluating patients’ injection experiences using the latest devices/formulations of the long-acting (LA) somatostatin analogs (SSAs) lanreotide Autogel/Depot (LAN; Somatuline®) and octreotide LA release (OCT; Sandostatin®) are limited. METHODS: PRESTO 2 was a 2020/2021...
Autores principales: | O’Toole, Dermot, Kunz, Pamela L., Webb, Susan M., Goldstein, Grace, Khawaja, Sheila, McDonnell, Mark, Boiziau, Sandra, Gueguen, Delphine, Houchard, Aude, Ribeiro-Oliveira, Antonio, Prebtani, Ally |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9741754/ https://www.ncbi.nlm.nih.gov/pubmed/36502449 http://dx.doi.org/10.1007/s12325-022-02360-6 |
Ejemplares similares
-
PMON57 Impact of Injection Modalities on Real-World Injection Experience in Patients with Acromegaly or Neuroendocrine Tumors (NETs) Treated With Somatostatin Analog (SSA) Therapy: Data from the PRESTO 2 Survey
por: Ribeiro-Oliveira, Antonio, et al.
Publicado: (2022) -
Resistance to Somatostatin Analogs in Italian Acromegaly Patients: The MISS Study
por: Berton, Alessandro Maria, et al.
Publicado: (2022) -
Prescription patterns of somatostatin analogs in patients with acromegaly and neuroendocrine tumors
por: Machado-Alba, J. E., et al.
Publicado: (2022) -
SUN-930 A Case of Acromegaly Secondary to Ectopic Growth Hormone-Releasing Hormone (GHRH) Secretion from a Bronchial Neuroendocrine Tumour
por: Bahrami, Jasmine, et al.
Publicado: (2020) -
Effects of somatostatin analog treatment on cardiovascular parameters in patients with acromegaly: A systematic review
por: Heidarpour, Maryam, et al.
Publicado: (2019)